argenx SE | ARGX - Selling And Administration Expenses

Stock Price
693.20
Daily Change
-1.00 -0.14%
Monthly
-2.45%
Yearly
37.43%
Q2 Forecast
656.38

argenx SE reported $355M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AstraZeneca USD 5.06B 455M Mar/2026
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Qiagen NV USD 153.88M 10.77M Dec/2025
UCB EUR 1.47B 193M Dec/2025